Computer-aided diagnostic tool for early detection of prostate cancer

Citations Over TimeTop 10% of 2016 papers

Abstract

In this paper, we propose a novel non-invasive framework for the early diagnosis of prostate cancer from diffusion-weighted magnetic resonance imaging (DW-MRI). The proposed approach consists of three main steps. In the first step, the prostate is localized and segmented based on a new level-set model. In the second step, the apparent diffusion coefficient (ADC) of the segmented prostate volume is mathematically calculated for different b-values. To preserve continuity, the calculated ADC values are normalized and refined using a Generalized Gauss-Markov Random Field (GGMRF) image model. The cumulative distribution function (CDF) of refined ADC for the prostate tissues at different b-values are then constructed. These CDFs are considered as global features describing water diffusion which can be used to distinguish between benign and malignant tumors. Finally, a deep learning auto-encoder network, trained by a stacked non-negativity constraint algorithm (SNCAE), is used to classify the prostate tumor as benign or malignant based on the CDFs extracted from the previous step. Preliminary experiments on 53 clinical DW-MRI data sets resulted in 100% correct classification, indicating the high accuracy of the proposed framework and holding promise of the proposed CAD system as a reliable non-invasive diagnostic tool.

Related Papers

• → Difference in Diffusion-Weighted Magnetic Resonance Imaging and Diffusion Tensor Imaging Parameters Between Endometrioid Endometrial Adenocarcinoma and Uterine Serous Adenocarcinoma(2017)13 cited
• → A Cancer-Indicative microRNA Pattern in Normal Prostate Tissue(2013)17 cited
• → Prostate cancers detected on repeat prostate biopsies show spatial distributions that differ from those detected on the initial biopsies(2014)7 cited
• → ANALYSIS OF FRACTIONAL ANISOTROPY (FA) VALUES AND APPARENT DIFFUSION COEFFICIENT (ADC) VALUES IN ISCHEMIC STROKE DISEASES OF MRI GE 3 TESLA(2019)
• → Can we improve the detection rate of prostate cancer using standard 12‐core TRUS‐guided prostate biopsy? Focused on the location of prostate biopsy(2020)